# On-site, high-fidelity target sequencing and absolute quantitation for HIV-1 surveillance

> **NIH NIH R01** · OHIO STATE UNIVERSITY · 2020 · $599,025

## Abstract

PROJECT SUMMARY / ABSTRACT
UNAIDS has set ambitious 90/90/90 targets toward ending the HIV/AIDS epidemic: that by 2020, 90% of
people living with HIV will know their HIV status; 90% of those diagnosed will be on sustained antiretroviral
treatment; and 90% of those on treatment will have achieved viral suppression. Reaching these goals will
require precise and efficient testing, patient care, and prevention interventions for key populations, particularly
in resource-limited settings. The genetic diversity of microbial pathogens – not just HIV-1 but any number of
pathogens for which antimicrobial drugs are being developed/employed – remains a major challenge for those
endeavoring to control them. Drug-resistance surveillance and the genotyping of microbial pathogens have
long been plagued by limited read lengths and erroneous sequencing. The proposed project will develop an
innovative sequencing and quantitation platform technology that can sensitively detect and accurately
delineate HIV-1 variants in patients through barcode-mediated, whole-genome sequencing using the so-called
“third-generation” Nanopore sequencing technology (Aims 1 and 2). Taking advantage of the pocket-size
mobility of the MinION Nanopore sequencer and other portable biotechnology devices that have recently
became available, we will further develop this technology for on-site and real-time surveillance and drug-
resistance diagnosis of emerging viruses even in resource-limited settings (Aim 3). Successful completion of
this study will produce a low-cost, ultra-high-accuracy sequencing and quantitation technology with broad
applicability to problems in diverse areas of science and medicine, from de novo genome assembly to point-of-
care drug-resistance genotyping. HIV-1 offers an excellent testbed for this technology due to the high degree
intra-patient genetic diversity and the need for on-site and genome-wide genotyping.

## Key facts

- **NIH application ID:** 9955309
- **Project number:** 5R01HG010318-03
- **Recipient organization:** OHIO STATE UNIVERSITY
- **Principal Investigator:** Sanggu Kim
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $599,025
- **Award type:** 5
- **Project period:** 2018-09-01 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9955309

## Citation

> US National Institutes of Health, RePORTER application 9955309, On-site, high-fidelity target sequencing and absolute quantitation for HIV-1 surveillance (5R01HG010318-03). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/9955309. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*